Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyu-Pyo Kim

Showing results (91-100 of 217) with videos related to

Pageof 22
Sort By:
Investigational New Drugs|December 31, 2009
A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunctionDok Hyun Yoon, Hyo Jung Lee, Yong Sang Hong, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 1, 2012
A positron emission tomography microdosing study with sertraline in healthy volunteersKwang-Hee Shin, Kyu-Pyo Kim, Kyoung Soo Lim, et al.
Targeted Oncology|September 27, 2019
Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center StudyJwa Hoon Kim, Sun Young Kim, Kyu-Pyo Kim, et al.
Oncotarget|October 21, 2016
Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer modelSi Yeol Song, Kyu-Pyo Kim, Seong-Yun Jeong, et al.
Investigational New Drugs|March 10, 2018
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapyHyungwoo Cho, Dok Hyun Yoon, Kyu-Pyo Kim, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2013
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancerKyu-pyo Kim, Ho-Sook Kim, Sun Jin Sym, et al.
Clinical Therapeutics|March 9, 2010
Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteersBo-Hyung Kim, Kyu-Pyo Kim, Kyoung Soo Lim, et al.
Journal of Hepatology|March 27, 2025
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trialsChanghoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
International Journal of Oncology|May 4, 2012
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1Yong Sang Hong, Seung-Woo Hong, Seung-Mi Kim, et al.
Cancer Research and Treatment|April 12, 2022
Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract CancerJihoon Kang, Ji-Young Lee, Sunmin Lee, et al.
Pageof 22

Showing results (91-100 of 217) with videos related to

Sort By:
Pageof 22
Investigational New Drugs|December 31, 2009
A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunctionDok Hyun Yoon, Hyo Jung Lee, Yong Sang Hong, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 1, 2012
A positron emission tomography microdosing study with sertraline in healthy volunteersKwang-Hee Shin, Kyu-Pyo Kim, Kyoung Soo Lim, et al.
Targeted Oncology|September 27, 2019
Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center StudyJwa Hoon Kim, Sun Young Kim, Kyu-Pyo Kim, et al.
Oncotarget|October 21, 2016
Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer modelSi Yeol Song, Kyu-Pyo Kim, Seong-Yun Jeong, et al.
Investigational New Drugs|March 10, 2018
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapyHyungwoo Cho, Dok Hyun Yoon, Kyu-Pyo Kim, et al.
Cancer Chemotherapy and Pharmacology|April 19, 2013
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancerKyu-pyo Kim, Ho-Sook Kim, Sun Jin Sym, et al.
Clinical Therapeutics|March 9, 2010
Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteersBo-Hyung Kim, Kyu-Pyo Kim, Kyoung Soo Lim, et al.
Journal of Hepatology|March 27, 2025
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trialsChanghoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
International Journal of Oncology|May 4, 2012
Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1Yong Sang Hong, Seung-Woo Hong, Seung-Mi Kim, et al.
Cancer Research and Treatment|April 12, 2022
Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract CancerJihoon Kang, Ji-Young Lee, Sunmin Lee, et al.
Pageof 22